

KIN-1902-2001: A Randomized, Double-blind, Placebo-controlled Phase 2 Study with Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects with Chronic Pulmonary Sarcoidosis

Status: Recruiting

Eligibility Criteria

Age: 18 years and over

This study is NOT accepting healthy

Healthy Volunteers: volunteers

Inclusion Criteria:

- Diagnosis of pulmonary sarcoidosis with some respiratory symptoms - If receiving prednisone, must be on a stable dose of 25 mg or less for 4 weeks - If receiving immunosuppressive therapy, must agree to stop if eligible to participate in the study - Completion of primary series of COVID-19 vaccination

Exclusion Criteria:

- Pregnancy or breast-feeding - Smoking or using any form of inhaled tobacco or cannabis within 6 months

Conditions & Interventions

Conditions:

Rare Diseases, Respiratory System

Keywords:

Clinics and Surgery Center (CSC), Sarcoidosis

More Information

Description: We are studying a new medication, namilumab, given to treat Chronic Pulmonary Sarcoidosis. We are looking at the effectiveness, how well the drug is tolerated, and the side effects that occur. For the first part of the study, some people will receive the namilumab; the others will receive an inactive (placebo) drug. In the second part of the study, everyone may receive the namilumab.

Contact(s): UMN Sarcoidosis Research Group Study - umnsarc@umn.edu

Principal Investigator: Maneesh Bhargava

IRB

Number: STUDY00014721

System ID: 36882

Thank you for choosing StudyFinder. Please visit <http://studyfinderstaging.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.